Stay updated with breaking news from Marcoa Zarbin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Chief among a flurry of clinical advances in retina disease this year were the FDA approvals of complement inhibitors for GA and a higher-dose aflibercept for diabetic retinopathy. What comes next?
In a pooled subcohort analysis of TENAYA and LUCERNE, faricimab showed comparable vision outcomes with fewer injections than aflibercept in DME eyes with baseline BCVA of ≤ 20/50.
Ocular Surgery News | As genetic counselors, we help patients to make informed decisions about genetic testing.We talk to them about what we know about the genetics of the condition and answer any questions, and then we order genetic testing for them, if that is something they want to do.